For some of the leading drugmakers, currently, the first priority is to find an effective treatment for Covid-19, which was declared a
AbbVie (NYSE: ABBV) topped revenue and earnings expectations for the fourth quarter of 2019, allowing the stock to gain over 3% in
With only a few weeks left for closing the high-value acquisition of Allergan, AbbVie (NYSE: ABBV) is busy doing the groundwork for
AbbVie Inc. (NYSE: ABBV) reported a 31% dip in earnings for the third quarter of 2019 due to higher costs and expenses.
Allergan plc (NYSE: AGN) continued to dominate in the tissue expander market as the demand for plastic surgeries is increasing from the
AbbVie's (NYSE: ABBV) earnings and revenue for the second quarter of 2019 surpassed Wall Street's estimates. AbbVie reported adjusted EPS of $2.26
AbbVie (NYSE: ABBV) is scheduled to report its earnings results for the second quarter of 2019 on Friday before the market opens.
AbbVie Inc. (ABBV) slipped to a loss in the fourth quarter from a profit last year, due to the inclusion of the